Pediatrics · 7 h ago
FDA Issues Temporary Compounding Guidance to Maintain Neonatal Parenteral Nutrition Access
The FDA has issued immediately effective guidance to address a potential supply gap in neonatal starter parenteral nutrition. The temporary policies follow concerns from children’s hospitals about discontinued products from two outsourcing facilities that are permanently shutting down.
- Temporary FDA guidance takes effect immediately.
- Two outsourcing facilities are permanently shutting down.
- Policies address specified neonatal starter PN products under sections 503A and 503B.
- FDA will monitor supply needs and consider further action.
The U.S. Food and Drug Administration has issued immediately effective guidance intended to maintain access to neonatal starter parenteral nutrition (PN) amid a potential supply gap. These intravenous products provide essential nutrients to premature and critically ill newborns who cannot receive nutrition orally or through a feeding tube. Children’s hospitals alerted the agency to access concerns following the discontinuation of certain standardized starter PN products made by two outsourcing facilities that are permanently shutting down.
The guidance, Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates, describes temporary regulatory and enforcement priorities for certain state-licensed pharmacies, federal facilities and outsourcing facilities. It covers specified parenteral drugs compounded under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The policies are intended to support hospital access while longer-term solutions are identified.
For neonatal care teams, the announcement addresses continuity of nutrition supply rather than changes to clinical treatment recommendations. The FDA describes a potential supply gap, not a confirmed nationwide shortage; the announcement does not quantify affected hospitals or anticipated supply volumes. The agency said it will continue monitoring current and expected supply needs and assess whether further action is necessary.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
U.S. Food and Drug Administration: FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.